 | • レポートコード：MRC2-11QY02816 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は体軸性脊椎関節炎薬のグローバル市場について調査・分析したレポートです。種類別（セルトリズマブペゴル、エタネルセプトバイオシミラー、イキセキズマブ、セクキヌマブ、その他）市場規模、用途別（クリニック、病院、在宅ケア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別体軸性脊椎関節炎薬の競争状況、市場シェア ・世界の体軸性脊椎関節炎薬市場：種類別市場規模 2015年-2020年（セルトリズマブペゴル、エタネルセプトバイオシミラー、イキセキズマブ、セクキヌマブ、その他） ・世界の体軸性脊椎関節炎薬市場：種類別市場規模予測 2021年-2026年（セルトリズマブペゴル、エタネルセプトバイオシミラー、イキセキズマブ、セクキヌマブ、その他） ・世界の体軸性脊椎関節炎薬市場：用途別市場規模 2015年-2020年（クリニック、病院、在宅ケア） ・世界の体軸性脊椎関節炎薬市場：用途別市場規模予測 2021年-2026年（クリニック、病院、在宅ケア） ・北米の体軸性脊椎関節炎薬市場分析：米国、カナダ ・ヨーロッパの体軸性脊椎関節炎薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの体軸性脊椎関節炎薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の体軸性脊椎関節炎薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの体軸性脊椎関節炎薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca Plc、Eli Lilly and Company、Johnson & Johnson、Novartis AG、Panacea Biotec Ltd、Sandoz International GmbH、Sun Pharma Advanced Research Company Ltd、UCB SA ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Axial Spondyloarthritis Drugs Market
The global Axial Spondyloarthritis Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Axial Spondyloarthritis Drugs Scope and Market Size
Axial Spondyloarthritis Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Axial Spondyloarthritis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Axial Spondyloarthritis Drugs market is segmented into
Certolizumab Pegol
Etanercept Biosimilar
Ixekizumab
Secukinumab
Others
Segment by Application, the Axial Spondyloarthritis Drugs market is segmented into
Clinic
Hospital
Home Care
Regional and Country-level Analysis
The Axial Spondyloarthritis Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Axial Spondyloarthritis Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Axial Spondyloarthritis Drugs Market Share Analysis
Axial Spondyloarthritis Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Axial Spondyloarthritis Drugs business, the date to enter into the Axial Spondyloarthritis Drugs market, Axial Spondyloarthritis Drugs product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca Plc
Eli Lilly and Company
Johnson & Johnson
Novartis AG
Panacea Biotec Ltd
Sandoz International GmbH
Sun Pharma Advanced Research Company Ltd
UCB SA
1 Study Coverage
1.1 Axial Spondyloarthritis Drugs Product Introduction
1.2 Market Segments
1.3 Key Axial Spondyloarthritis Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Type
1.4.2 Certolizumab Pegol
1.4.3 Etanercept Biosimilar
1.4.4 Ixekizumab
1.4.5 Secukinumab
1.4.6 Others
1.5 Market by Application
1.5.1 Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Home Care
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Axial Spondyloarthritis Drugs Market Size, Estimates and Forecasts
2.1.1 Global Axial Spondyloarthritis Drugs Revenue 2015-2026
2.1.2 Global Axial Spondyloarthritis Drugs Sales 2015-2026
2.2 Global Axial Spondyloarthritis Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Axial Spondyloarthritis Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Axial Spondyloarthritis Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Axial Spondyloarthritis Drugs Competitor Landscape by Players
3.1 Axial Spondyloarthritis Drugs Sales by Manufacturers
3.1.1 Axial Spondyloarthritis Drugs Sales by Manufacturers (2015-2020)
3.1.2 Axial Spondyloarthritis Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Axial Spondyloarthritis Drugs Revenue by Manufacturers
3.2.1 Axial Spondyloarthritis Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Axial Spondyloarthritis Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Axial Spondyloarthritis Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Axial Spondyloarthritis Drugs Revenue in 2019
3.2.5 Global Axial Spondyloarthritis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Axial Spondyloarthritis Drugs Price by Manufacturers
3.4 Axial Spondyloarthritis Drugs Manufacturing Base Distribution, Product Types
3.4.1 Axial Spondyloarthritis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Axial Spondyloarthritis Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Axial Spondyloarthritis Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Axial Spondyloarthritis Drugs Market Size by Type (2015-2020)
4.1.1 Global Axial Spondyloarthritis Drugs Sales by Type (2015-2020)
4.1.2 Global Axial Spondyloarthritis Drugs Revenue by Type (2015-2020)
4.1.3 Axial Spondyloarthritis Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Axial Spondyloarthritis Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Axial Spondyloarthritis Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Axial Spondyloarthritis Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Axial Spondyloarthritis Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Axial Spondyloarthritis Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Axial Spondyloarthritis Drugs Market Size by Application (2015-2020)
5.1.1 Global Axial Spondyloarthritis Drugs Sales by Application (2015-2020)
5.1.2 Global Axial Spondyloarthritis Drugs Revenue by Application (2015-2020)
5.1.3 Axial Spondyloarthritis Drugs Price by Application (2015-2020)
5.2 Axial Spondyloarthritis Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Axial Spondyloarthritis Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Axial Spondyloarthritis Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Axial Spondyloarthritis Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Axial Spondyloarthritis Drugs by Country
6.1.1 North America Axial Spondyloarthritis Drugs Sales by Country
6.1.2 North America Axial Spondyloarthritis Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Axial Spondyloarthritis Drugs Market Facts & Figures by Type
6.3 North America Axial Spondyloarthritis Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Axial Spondyloarthritis Drugs by Country
7.1.1 Europe Axial Spondyloarthritis Drugs Sales by Country
7.1.2 Europe Axial Spondyloarthritis Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Axial Spondyloarthritis Drugs Market Facts & Figures by Type
7.3 Europe Axial Spondyloarthritis Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Axial Spondyloarthritis Drugs by Region
8.1.1 Asia Pacific Axial Spondyloarthritis Drugs Sales by Region
8.1.2 Asia Pacific Axial Spondyloarthritis Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Axial Spondyloarthritis Drugs Market Facts & Figures by Type
8.3 Asia Pacific Axial Spondyloarthritis Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Axial Spondyloarthritis Drugs by Country
9.1.1 Latin America Axial Spondyloarthritis Drugs Sales by Country
9.1.2 Latin America Axial Spondyloarthritis Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Axial Spondyloarthritis Drugs Market Facts & Figures by Type
9.3 Central & South America Axial Spondyloarthritis Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Axial Spondyloarthritis Drugs by Country
10.1.1 Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country
10.1.2 Middle East and Africa Axial Spondyloarthritis Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Axial Spondyloarthritis Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Axial Spondyloarthritis Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Corporation Information
11.1.2 AstraZeneca Plc Description and Business Overview
11.1.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Plc Axial Spondyloarthritis Drugs Products Offered
11.1.5 AstraZeneca Plc Related Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Corporation Information
11.2.2 Eli Lilly and Company Description and Business Overview
11.2.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Eli Lilly and Company Axial Spondyloarthritis Drugs Products Offered
11.2.5 Eli Lilly and Company Related Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Description and Business Overview
11.3.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Johnson & Johnson Axial Spondyloarthritis Drugs Products Offered
11.3.5 Johnson & Johnson Related Developments
11.4 Novartis AG
11.4.1 Novartis AG Corporation Information
11.4.2 Novartis AG Description and Business Overview
11.4.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novartis AG Axial Spondyloarthritis Drugs Products Offered
11.4.5 Novartis AG Related Developments
11.5 Panacea Biotec Ltd
11.5.1 Panacea Biotec Ltd Corporation Information
11.5.2 Panacea Biotec Ltd Description and Business Overview
11.5.3 Panacea Biotec Ltd Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Products Offered
11.5.5 Panacea Biotec Ltd Related Developments
11.6 Sandoz International GmbH
11.6.1 Sandoz International GmbH Corporation Information
11.6.2 Sandoz International GmbH Description and Business Overview
11.6.3 Sandoz International GmbH Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Sandoz International GmbH Axial Spondyloarthritis Drugs Products Offered
11.6.5 Sandoz International GmbH Related Developments
11.7 Sun Pharma Advanced Research Company Ltd
11.7.1 Sun Pharma Advanced Research Company Ltd Corporation Information
11.7.2 Sun Pharma Advanced Research Company Ltd Description and Business Overview
11.7.3 Sun Pharma Advanced Research Company Ltd Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Products Offered
11.7.5 Sun Pharma Advanced Research Company Ltd Related Developments
11.8 UCB SA
11.8.1 UCB SA Corporation Information
11.8.2 UCB SA Description and Business Overview
11.8.3 UCB SA Sales, Revenue and Gross Margin (2015-2020)
11.8.4 UCB SA Axial Spondyloarthritis Drugs Products Offered
11.8.5 UCB SA Related Developments
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Corporation Information
11.1.2 AstraZeneca Plc Description and Business Overview
11.1.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Plc Axial Spondyloarthritis Drugs Products Offered
11.1.5 AstraZeneca Plc Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Axial Spondyloarthritis Drugs Market Estimates and Projections by Region
12.1.1 Global Axial Spondyloarthritis Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Axial Spondyloarthritis Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Axial Spondyloarthritis Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Axial Spondyloarthritis Drugs Sales Forecast (2021-2026)
12.2.2 North America: Axial Spondyloarthritis Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Axial Spondyloarthritis Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Axial Spondyloarthritis Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Axial Spondyloarthritis Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Axial Spondyloarthritis Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Axial Spondyloarthritis Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Axial Spondyloarthritis Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Axial Spondyloarthritis Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Axial Spondyloarthritis Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Axial Spondyloarthritis Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Axial Spondyloarthritis Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Axial Spondyloarthritis Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Axial Spondyloarthritis Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Axial Spondyloarthritis Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Axial Spondyloarthritis Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Axial Spondyloarthritis Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Axial Spondyloarthritis Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Axial Spondyloarthritis Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Axial Spondyloarthritis Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Axial Spondyloarthritis Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Axial Spondyloarthritis Drugs Market Segments
Table 2. Ranking of Global Top Axial Spondyloarthritis Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Certolizumab Pegol
Table 5. Major Manufacturers of Etanercept Biosimilar
Table 6. Major Manufacturers of Ixekizumab
Table 7. Major Manufacturers of Secukinumab
Table 8. Major Manufacturers of Others
Table 9. Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Axial Spondyloarthritis Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Axial Spondyloarthritis Drugs Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Axial Spondyloarthritis Drugs Sales Market Share by Regions (2015-2020)
Table 13. Global Axial Spondyloarthritis Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Axial Spondyloarthritis Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Axial Spondyloarthritis Drugs Sales Share by Manufacturers (2015-2020)
Table 16. Global Axial Spondyloarthritis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Axial Spondyloarthritis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Axial Spondyloarthritis Drugs as of 2019)
Table 18. Axial Spondyloarthritis Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Axial Spondyloarthritis Drugs Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Axial Spondyloarthritis Drugs Price (2015-2020) (USD/Pcs)
Table 21. Axial Spondyloarthritis Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Axial Spondyloarthritis Drugs Product Type
Table 23. Date of International Manufacturers Enter into Axial Spondyloarthritis Drugs Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Axial Spondyloarthritis Drugs Sales by Type (2015-2020) (K Pcs)
Table 26. Global Axial Spondyloarthritis Drugs Sales Share by Type (2015-2020)
Table 27. Global Axial Spondyloarthritis Drugs Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Axial Spondyloarthritis Drugs Revenue Share by Type (2015-2020)
Table 29. Axial Spondyloarthritis Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Axial Spondyloarthritis Drugs Sales by Application (2015-2020) (K Pcs)
Table 31. Global Axial Spondyloarthritis Drugs Sales Share by Application (2015-2020)
Table 32. North America Axial Spondyloarthritis Drugs Sales by Country (2015-2020) (K Pcs)
Table 33. North America Axial Spondyloarthritis Drugs Sales Market Share by Country (2015-2020)
Table 34. North America Axial Spondyloarthritis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Axial Spondyloarthritis Drugs Revenue Market Share by Country (2015-2020)
Table 36. North America Axial Spondyloarthritis Drugs Sales by Type (2015-2020) (K Pcs)
Table 37. North America Axial Spondyloarthritis Drugs Sales Market Share by Type (2015-2020)
Table 38. North America Axial Spondyloarthritis Drugs Sales by Application (2015-2020) (K Pcs)
Table 39. North America Axial Spondyloarthritis Drugs Sales Market Share by Application (2015-2020)
Table 40. Europe Axial Spondyloarthritis Drugs Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Axial Spondyloarthritis Drugs Sales Market Share by Country (2015-2020)
Table 42. Europe Axial Spondyloarthritis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Axial Spondyloarthritis Drugs Revenue Market Share by Country (2015-2020)
Table 44. Europe Axial Spondyloarthritis Drugs Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Axial Spondyloarthritis Drugs Sales Market Share by Type (2015-2020)
Table 46. Europe Axial Spondyloarthritis Drugs Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Axial Spondyloarthritis Drugs Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Axial Spondyloarthritis Drugs Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Axial Spondyloarthritis Drugs Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Axial Spondyloarthritis Drugs Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Axial Spondyloarthritis Drugs Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Axial Spondyloarthritis Drugs Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Axial Spondyloarthritis Drugs Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Axial Spondyloarthritis Drugs Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Axial Spondyloarthritis Drugs Sales Market Share by Application (2015-2020)
Table 56. Latin America Axial Spondyloarthritis Drugs Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Axial Spondyloarthritis Drugs Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Axial Spondyloarthritis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Axial Spondyloarthritis Drugs Revenue Market Share by Country (2015-2020)
Table 60. Latin America Axial Spondyloarthritis Drugs Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Axial Spondyloarthritis Drugs Sales Market Share by Type (2015-2020)
Table 62. Latin America Axial Spondyloarthritis Drugs Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Axial Spondyloarthritis Drugs Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Axial Spondyloarthritis Drugs Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Axial Spondyloarthritis Drugs Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Axial Spondyloarthritis Drugs Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Axial Spondyloarthritis Drugs Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Axial Spondyloarthritis Drugs Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Axial Spondyloarthritis Drugs Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Axial Spondyloarthritis Drugs Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Axial Spondyloarthritis Drugs Sales Market Share by Application (2015-2020)
Table 72. AstraZeneca Plc Corporation Information
Table 73. AstraZeneca Plc Description and Major Businesses
Table 74. AstraZeneca Plc Axial Spondyloarthritis Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. AstraZeneca Plc Product
Table 76. AstraZeneca Plc Recent Development
Table 77. Eli Lilly and Company Corporation Information
Table 78. Eli Lilly and Company Description and Major Businesses
Table 79. Eli Lilly and Company Axial Spondyloarthritis Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Eli Lilly and Company Product
Table 81. Eli Lilly and Company Recent Development
Table 82. Johnson & Johnson Corporation Information
Table 83. Johnson & Johnson Description and Major Businesses
Table 84. Johnson & Johnson Axial Spondyloarthritis Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Johnson & Johnson Product
Table 86. Johnson & Johnson Recent Development
Table 87. Novartis AG Corporation Information
Table 88. Novartis AG Description and Major Businesses
Table 89. Novartis AG Axial Spondyloarthritis Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Novartis AG Product
Table 91. Novartis AG Recent Development
Table 92. Panacea Biotec Ltd Corporation Information
Table 93. Panacea Biotec Ltd Description and Major Businesses
Table 94. Panacea Biotec Ltd Axial Spondyloarthritis Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Panacea Biotec Ltd Product
Table 96. Panacea Biotec Ltd Recent Development
Table 97. Sandoz International GmbH Corporation Information
Table 98. Sandoz International GmbH Description and Major Businesses
Table 99. Sandoz International GmbH Axial Spondyloarthritis Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Sandoz International GmbH Product
Table 101. Sandoz International GmbH Recent Development
Table 102. Sun Pharma Advanced Research Company Ltd Corporation Information
Table 103. Sun Pharma Advanced Research Company Ltd Description and Major Businesses
Table 104. Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Sun Pharma Advanced Research Company Ltd Product
Table 106. Sun Pharma Advanced Research Company Ltd Recent Development
Table 107. UCB SA Corporation Information
Table 108. UCB SA Description and Major Businesses
Table 109. UCB SA Axial Spondyloarthritis Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. UCB SA Product
Table 111. UCB SA Recent Development
Table 112. Global Axial Spondyloarthritis Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 113. Global Axial Spondyloarthritis Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 114. Global Axial Spondyloarthritis Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 115. Global Axial Spondyloarthritis Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 116. North America: Axial Spondyloarthritis Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 117. North America: Axial Spondyloarthritis Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 118. Europe: Axial Spondyloarthritis Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 119. Europe: Axial Spondyloarthritis Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 120. Asia Pacific: Axial Spondyloarthritis Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 121. Asia Pacific: Axial Spondyloarthritis Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 122. Latin America: Axial Spondyloarthritis Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 123. Latin America: Axial Spondyloarthritis Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 124. Middle East and Africa: Axial Spondyloarthritis Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 125. Middle East and Africa: Axial Spondyloarthritis Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 126. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 127. Key Challenges
Table 128. Market Risks
Table 129. Main Points Interviewed from Key Axial Spondyloarthritis Drugs Players
Table 130. Axial Spondyloarthritis Drugs Customers List
Table 131. Axial Spondyloarthritis Drugs Distributors List
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Axial Spondyloarthritis Drugs Product Picture
Figure 2. Global Axial Spondyloarthritis Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Certolizumab Pegol Product Picture
Figure 4. Etanercept Biosimilar Product Picture
Figure 5. Ixekizumab Product Picture
Figure 6. Secukinumab Product Picture
Figure 7. Others Product Picture
Figure 8. Global Axial Spondyloarthritis Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Clinic
Figure 10. Hospital
Figure 11. Home Care
Figure 12. Axial Spondyloarthritis Drugs Report Years Considered
Figure 13. Global Axial Spondyloarthritis Drugs Market Size 2015-2026 (US$ Million)
Figure 14. Global Axial Spondyloarthritis Drugs Sales 2015-2026 (K Pcs)
Figure 15. Global Axial Spondyloarthritis Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Axial Spondyloarthritis Drugs Sales Market Share by Region (2015-2020)
Figure 17. Global Axial Spondyloarthritis Drugs Sales Market Share by Region in 2019
Figure 18. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region (2015-2020)
Figure 19. Global Axial Spondyloarthritis Drugs Revenue Market Share by Region in 2019
Figure 20. Global Axial Spondyloarthritis Drugs Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Axial Spondyloarthritis Drugs Revenue in 2019
Figure 22. Axial Spondyloarthritis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Axial Spondyloarthritis Drugs Sales Market Share by Type (2015-2020)
Figure 24. Global Axial Spondyloarthritis Drugs Sales Market Share by Type in 2019
Figure 25. Global Axial Spondyloarthritis Drugs Revenue Market Share by Type (2015-2020)
Figure 26. Global Axial Spondyloarthritis Drugs Revenue Market Share by Type in 2019
Figure 27. Global Axial Spondyloarthritis Drugs Market Share by Price Range (2015-2020)
Figure 28. Global Axial Spondyloarthritis Drugs Sales Market Share by Application (2015-2020)
Figure 29. Global Axial Spondyloarthritis Drugs Sales Market Share by Application in 2019
Figure 30. Global Axial Spondyloarthritis Drugs Revenue Market Share by Application (2015-2020)
Figure 31. Global Axial Spondyloarthritis Drugs Revenue Market Share by Application in 2019
Figure 32. North America Axial Spondyloarthritis Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Axial Spondyloarthritis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Axial Spondyloarthritis Drugs Sales Market Share by Country in 2019
Figure 35. North America Axial Spondyloarthritis Drugs Revenue Market Share by Country in 2019
Figure 36. U.S. Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Axial Spondyloarthritis Drugs Market Share by Type in 2019
Figure 41. North America Axial Spondyloarthritis Drugs Market Share by Application in 2019
Figure 42. Europe Axial Spondyloarthritis Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Axial Spondyloarthritis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Axial Spondyloarthritis Drugs Sales Market Share by Country in 2019
Figure 45. Europe Axial Spondyloarthritis Drugs Revenue Market Share by Country in 2019
Figure 46. Germany Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Axial Spondyloarthritis Drugs Market Share by Type in 2019
Figure 57. Europe Axial Spondyloarthritis Drugs Market Share by Application in 2019
Figure 58. Asia Pacific Axial Spondyloarthritis Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Axial Spondyloarthritis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Axial Spondyloarthritis Drugs Sales Market Share by Region in 2019
Figure 61. Asia Pacific Axial Spondyloarthritis Drugs Revenue Market Share by Region in 2019
Figure 62. China Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Axial Spondyloarthritis Drugs Market Share by Type in 2019
Figure 85. Asia Pacific Axial Spondyloarthritis Drugs Market Share by Application in 2019
Figure 86. Latin America Axial Spondyloarthritis Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Axial Spondyloarthritis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Axial Spondyloarthritis Drugs Sales Market Share by Country in 2019
Figure 89. Latin America Axial Spondyloarthritis Drugs Revenue Market Share by Country in 2019
Figure 90. Mexico Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Axial Spondyloarthritis Drugs Market Share by Type in 2019
Figure 97. Latin America Axial Spondyloarthritis Drugs Market Share by Application in 2019
Figure 98. Middle East and Africa Axial Spondyloarthritis Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Axial Spondyloarthritis Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Axial Spondyloarthritis Drugs Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Axial Spondyloarthritis Drugs Revenue Market Share by Country in 2019
Figure 102. Turkey Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Axial Spondyloarthritis Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Axial Spondyloarthritis Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Axial Spondyloarthritis Drugs Market Share by Type in 2019
Figure 109. Middle East and Africa Axial Spondyloarthritis Drugs Market Share by Application in 2019
Figure 110. North America Axial Spondyloarthritis Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Axial Spondyloarthritis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Axial Spondyloarthritis Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Axial Spondyloarthritis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Axial Spondyloarthritis Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Axial Spondyloarthritis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Axial Spondyloarthritis Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Axial Spondyloarthritis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Axial Spondyloarthritis Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Axial Spondyloarthritis Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
軸方向/ねじり試験システムの世界市場（～2026年） Combined axial and torsional loading, or biaxial tests are common to metals testing, biomechanics, tissue engineering, orthopedics and composites testing applications. Market Analysis and Insights: Global Axial / Torsional Test Systems Market The global Axial / Torsional Test Systems market size is …- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…
- 潰瘍性大腸炎免疫薬 の世界市場（～2026年） Market Analysis and Insights: Global Ulcerative Colitis Immunology Drugs Market The global Ulcerative Colitis Immunology Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Ulcerative Colitis Immunology Drugs Scope a…
- テネクテプラーゼ薬の世界市場（～2026年） Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. It is estimated that North America dominated the…
- 自己免疫治療薬の世界市場（～2026年） Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by c…